IPSC 財務： Century Therapeutics Inc AI 分析



財務狀況

IPSC 財務

Century Therapeutics Inc

$2.25

1.35%

$0.02

收盤價：Apr 27, 16:00:00 GMT-4

$2.28

1.33%

$0.02

盤前：Apr 28, 09:23:28 GMT-4

概觀預測收益股利財務狀況

關鍵數據

前收市價

$2.22

開盤價

$2.23

當日範圍

$2.22 - $2.31

52週區間

$0.435 - $3.04

交易量

490.5K

平均成交量

1.7M

股息收益率

每股盈餘 (TTM)

-0.11

市值

$409.7M

什麼是 IPSC？

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 78 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

功能特性

資源

市場

收入

資產負債表

現金流量

年度

每季

IPSC 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
營收	109	0	0	0	109	4
營收年增率 (YoY)	1,717%	-100%	--	--	--	--
營收成本	--	--	--	--	--	--
毛利	--	--	--	--	--	--
銷售、一般及管理費用	24	0	6	7	8	7
研發	95	19	22	26	26	29
營業費用	119	20	29	34	34	37
其他非營業收入 (費用)	0	0	0	0	0	0
稅前淨利	-9	-19	-34	-32	76	-34
所得稅費用	0	0	0	--	0	1
淨利	-9	-19	-34	-32	76	-36
淨利成長	-93%	-47%	10%	3%	-371%	-8%
稀釋後流通股數	87.28	87.28	86.46	86.23	86.09	85.41
股數年變動 (YoY)	2%	2%	2%	5%	39%	42%
每股盈餘 (稀釋)	-0.1	-0.21	-0.39	-0.37	0.88	-0.42
每股盈餘成長率	-93%	-48%	8%	-1%	-298%	-36%
自由現金流	-104	-15	-25	-27	-35	-24
每股自由現金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
營業利益率	-9.17%	0%	0%	0%	67.88%	-800%
淨利率	-8.25%	0%	0%	0%	69.72%	-900%
自由現金流利潤率	-95.41%	0%	0%	0%	-32.11%	-600%
EBITDA	3	-17	-26	-31	77	-29
EBITDA 利潤率	2.75%	0%	0%	0%	70.64%	-725%
EBITDA 中的折舊與攤銷	13	3	3	3	3	3
EBIT	-10	-20	-29	-34	74	-32
EBIT 利潤率	-9.17%	0%	0%	0%	67.88%	-800%
有效稅率	0%	0%	0%	--	0%	-2.94%

Follow-Up Questions

Century Therapeutics Inc 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Century Therapeutics Inc 的總資產為 $0，淨損失為 $0

IPSC 的關鍵財務比率是什麼？



Century Therapeutics Inc 的流動比率為 0，淨利潤率為 0，每股銷售為 $0。

Century Therapeutics Inc 的收入按細分市場或地理位置如何劃分？



Century Therapeutics Inc 最大收入來源為 Allogeneic Cell Therapies，在最近的收益報告中收入為 109,164,000。就地區而言，United States 是 Century Therapeutics Inc 的主要市場，收入為 109,164,000。

Century Therapeutics Inc 是否盈利？



無，根據最新的財務報表，Century Therapeutics Inc 的淨損失為 $0

Century Therapeutics Inc 有負債嗎？



無，Century Therapeutics Inc 的負債為 0

Century Therapeutics Inc 的流通股有多少？



Century Therapeutics Inc 的總流通股為 0

Century Therapeutics Inc (IPSC) 財務

IPSC 股價走勢圖